A 2-year prospective, observational study enrolled treatment experienced PWH following the decision to switch to CAB+RPV LA (monthly or every 2 months)
Latest Information Update: 16 Jul 2025
At a glance
- Drugs Cabotegravir+rilpivirine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms BEYOND
Most Recent Events
- 08 Jul 2025 According to ViiV Healthcare media release, data this study will be presented at the International AIDS Society 2025 Conference (IAS 2025) in Kigali, Rwanda.
- 01 Jun 2025 Results(n=71) showing During the first year of treatment, LACR does not significantly impact the HIV reservoir. However, it may reduce immune activation, particularly in persons switching from a dual therapy regimen were published in the HIV Medicine
- 15 Jul 2024 According to a ViiV Healthcare media release, results form this study will be presented at the 25th International AIDS Conference in Munich, Germany (22 -26 July).